SCTX
Scribe Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-51/100
Last price
16.56
▲ 0.35 (2.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
16.56
Prev close
16.21
Day high
17.17
Day low
15.37
Volume
464.46K
Market cap
$309.15M
P/E (TTM)
—
52W range
13.50 – 39.60
Day trading desk
Gap from prior close
+2.16%
Prior close 16.21
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
16.56 – 16.56
Position in range
—
—
ATR (14D)
3.61
21.78% of price
Prior day high
17.17
PDH
Prior day low
13.50
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 356.27K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-29.09%
-31.0%
1M
-43.04%
-44.2%
3M
—
-4.5%
6M
—
-18.2%
YTD
-13.92%
-28.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SCTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.03M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 28, 26 | AGHAZADEH BEHZAD PH.D. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.39M | $51.78M | Indirect |
| Jul 27, 26 | GORDON CARL L Director |
BUY | 1.00M | $18.97M | Indirect |
| Jul 27, 26 | GORDON CARL L Director |
— | 348.82K | — | Indirect |
| Jul 27, 26 | ORBIMED ADVISORS, L.L.C. Director |
BUY | 1.00M | $18.97M | Indirect |
| Jul 27, 26 | ORBIMED ADVISORS, L.L.C. Director |
— | 348.82K | — | Indirect |
| Jul 27, 26 | DOUDNA JENNIFER A. PH.D. Beneficial Owner of more than 10% of a Class of Security |
— | 12.51K | — | Direct |
| Jul 27, 26 | AH BIO FUND II LP Beneficial Owner of more than 10% of a Class of Security |
BUY | 333.33K | $6.32M | Indirect |
| Jul 27, 26 | AH BIO FUND II LP Beneficial Owner of more than 10% of a Class of Security |
— | 2.75M | — | Indirect |
| Jul 23, 26 | LUCAS SVETLANA Officer |
BUY | 3.00K | $45.00K | Indirect |
| Jul 23, 26 | PARROT DAVID L. Chief Financial Officer |
BUY | 2.67K | $39.99K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGHAZADEH BEHZAD PH.D. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
AH BIO FUND II LP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
DOUDNA JENNIFER A. PH.D. |
Beneficial Owner of more than 10% of a Class of Security | 603.55K | Conversion of Exercise of derivative security |
GORDON CARL L |
Director | — | Purchase |
LUCAS SVETLANA |
Officer | — | Purchase |
ORBIMED ADVISORS, L.L.C. |
Director | — | Purchase |
PARROT DAVID L. |
Chief Financial Officer | — | Purchase |
Fundamentals
Market cap$309.15M
Enterprise value$429.77M
Revenue (TTM)$33.30M
Gross profit$-17.75M
EBITDA$-27.82M
Net income$-32.30M
EPS (TTM)$-3.84
Free cash flow—
Total cash$43.01M
Total debt$43.27M
Book value / share$-66.33
Shares outstanding18.93M
Float6.89M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.52
PEG ratio—
Price / sales—
Price / book—
EV / revenue12.91
EV / EBITDA-15.45
Gross margin-53.29%
Operating margin-489.83%
Profit margin-97.00%
Return on equity—
Return on assets—
Debt / equity—
Current ratio0.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $51.17M | $27.41M | +86.7% |
| Operating revenue | $51.17M | $27.41M | +86.7% |
| Research & development | $60.80M | $57.08M | +6.5% |
| Selling, general & admin | $16.45M | $13.16M | +25.0% |
| Total operating expense | $77.24M | $70.24M | +10.0% |
| Operating income | -$26.07M | -$42.83M | +39.1% |
| Net interest income | $933.00K | $3.77M | -75.3% |
| Pre-tax income | -$23.61M | -$37.56M | +37.1% |
| Tax provision | -$1.80M | $10.22M | -117.6% |
| Net income | -$21.81M | -$47.79M | +54.4% |
| Net income to common | -$21.81M | -$47.79M | +54.4% |
| EBIT | -$21.22M | -$35.18M | +39.7% |
| EBITDA | -$18.14M | -$32.29M | +43.8% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $12.80M | $12.60M | +1.5% |
| Cash & short-term investments | $57.96M | $105.17M | -44.9% |
| Total current assets | $66.93M | $110.37M | -39.4% |
| Property, plant & equipment | $10.07M | $13.18M | -23.6% |
| Total assets | $78.22M | $127.97M | -38.9% |
| Total current liabilities | $69.06M | $35.02M | +97.2% |
| Current debt | $35.34M | — | — |
| Long-term debt | — | $34.47M | — |
| Total debt | $41.43M | $41.68M | -0.6% |
| Total liabilities | $221.64M | $253.83M | -12.7% |
| Retained earnings | -$157.71M | -$135.90M | -16.0% |
| Shareholder equity | -$143.42M | -$125.86M | -14.0% |
| Working capital | -$2.12M | $75.36M | -102.8% |
| Net tangible assets | -$143.42M | -$125.86M | -14.0% |
| Shares issued | 17.58M | 17.58M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$21.81M | -$47.79M | +54.4% |
| Depreciation & amortisation | $3.08M | $2.89M | +6.5% |
| Stock-based compensation | $4.14M | $2.85M | +45.5% |
| Change in working capital | -$36.39M | -$5.22M | -597.2% |
| Operating cash flow | -$45.21M | -$45.23M | +0.0% |
| Capital expenditure | -$1.27M | -$1.35M | +5.8% |
| Investing cash flow | $45.27M | $13.01M | +247.8% |
| Financing cash flow | $142.00K | -$222.00K | +164.0% |
| Free cash flow | -$46.48M | -$46.58M | +0.2% |
| End cash position | $13.47M | $13.28M | +1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.92M | $2.23M | $4.90M | $17.13M | -14.1% |
| Operating revenue | $1.92M | $2.23M | $4.90M | $17.13M | -14.1% |
| Research & development | $8.82M | $11.30M | $13.88M | $15.99M | -22.0% |
| Selling, general & admin | $2.49M | $3.35M | $2.64M | $6.69M | -25.8% |
| Total operating expense | $11.31M | $14.66M | $16.52M | $22.68M | -22.8% |
| Operating income | -$9.39M | -$12.43M | -$11.63M | -$5.56M | +24.4% |
| Net interest income | $107.00K | -$83.00K | $282.00K | $465.00K | +228.9% |
| Pre-tax income | -$6.26M | -$17.12M | -$10.62M | -$3.74M | +63.4% |
| Tax provision | $212.00K | $228.00K | -$712.00K | -$315.00K | -7.0% |
| Net income | -$6.48M | -$17.35M | -$9.90M | -$3.42M | +62.7% |
| Net income to common | -$6.48M | -$17.35M | -$9.90M | -$3.42M | +62.7% |
| Basic EPS | -0.37 | — | -1.17 | — | — |
| Diluted EPS | -0.37 | — | -1.17 | — | — |
| EBIT | -$5.99M | -$16.52M | -$10.02M | -$3.14M | +63.7% |
| EBITDA | -$5.20M | -$15.75M | -$9.18M | -$2.28M | +67.0% |
| Basic shares | 16.18M | — | 8.43M | — | — |
| Diluted shares | 16.18M | — | 8.43M | — | — |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $35.59M | $20.38M | +74.6% |
| Cash & short-term investments | $43.01M | $49.73M | -13.5% |
| Total current assets | $45.10M | $52.40M | -13.9% |
| Property, plant & equipment | $8.54M | $9.32M | -8.4% |
| Total assets | $57.93M | $65.21M | -11.2% |
| Total current liabilities | $78.70M | $79.72M | -1.3% |
| Current debt | $37.80M | $40.55M | -6.8% |
| Total debt | $43.27M | $46.33M | -6.6% |
| Total liabilities | $222.77M | $223.95M | -0.5% |
| Retained earnings | -$181.53M | -$175.05M | -3.7% |
| Shareholder equity | -$164.85M | -$158.74M | -3.8% |
| Working capital | -$33.59M | -$27.32M | -23.0% |
| Net tangible assets | -$164.85M | -$158.74M | -3.8% |
| Shares issued | 17.58M | 17.58M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$6.48M | -$17.35M | -$9.90M | -$3.42M | +62.7% |
| Depreciation & amortisation | $785.00K | $773.00K | $836.00K | $862.00K | +1.6% |
| Stock-based compensation | $227.00K | $1.97M | $676.00K | $671.00K | -88.5% |
| Change in working capital | -$952.00K | $1.63M | $1.57M | -$14.72M | -158.6% |
| Operating cash flow | -$5.34M | -$7.55M | -$6.63M | -$13.62M | +29.4% |
| Capital expenditure | -$10.00K | -$17.00K | -$439.00K | -$491.00K | +41.2% |
| Investing cash flow | $21.92M | $15.55M | $2.66M | $20.92M | +40.9% |
| Financing cash flow | -$1.38M | -$411.00K | $53.00K | -$2.00K | -235.0% |
| Free cash flow | -$5.35M | -$7.57M | -$7.07M | -$14.11M | +29.4% |
| End cash position | $36.26M | $21.06M | $16.66M | $20.57M | +72.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -3.72 | -2.62 | +29.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.03 | 3 | $3.72M | — |
| Next quarter | -1.06 | 3 | $3.71M | — |
| Current year | -5.59 | 2 | $11.57M | — |
| Next year | -3.62 | 3 | $6.73M | -41.8% |
Analyst targets & ownership
Mean target$57.00
High target$60.00
Low target$50.00
Implied upside244.20%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders10.70%
Held by institutions54.46%
Institutions holding19
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.91
-16.84% from price
SMA 20
24.96
-34.58% from price
SMA 50
25.82
-36.76% from price
SMA 100
—
—
SMA 200
—
—
EMA 12
20.71
-20.05% from price
EMA 26
23.58
-29.76% from price
EMA 50
25.50
-35.06% from price
RSI (14)
32.1
Neutral
MACD (12,26,9)
-2.86
Hist -1.39
ATR (14)
3.61
22.08% of price
Realised vol 30D
130.4%
Annualised
Bollinger upper
36.30
20, 2σ
Bollinger lower
13.62
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
130.4%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-56.5%
Peak to trough
Max drawdown 5Y
-56.5%
Peak to trough
ATR 14
3.61
22.08% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
790.54K
Prior 284.71K
Change vs prior
+177.7%
Shorts adding
% of float
—
—
% of shares out
4.18%
Against total outstanding
Days to cover
3.3
Liquid
Float
6.89M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 31, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 18, 26 | Wells Fargo | INITIATED | — | Overweight |
| Aug 18, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 18, 26 | Guggenheim | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-02
Offering Registrations
S-1MEF · 2026-07-23
Trading Registrations
8-A12B · 2026-07-21
Offering Registrations
S-1/A · 2026-07-20
Offering Registrations
S-1 · 2026-07-02
Offering Registrations
DRS/A · 2026-06-12
Offering Registrations
DRS/A · 2026-03-06
Offering Registrations
DRS · 2026-01-09
Headlines
Cathie Wood Makes $64 Million Bet on Two Stocks
GuruFocus.com · 9d ago
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
Stocktwits · 15d ago
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Investor's Business Daily · 20d ago
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 35d ago
Scribe Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · 36d ago
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
The Fly · 37d ago
Top Premarket Gainers
MT Newswires · 44d ago
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
The Fly · 50d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.